HOME >> MEDICINE >> NEWS
PET scans superior in revealing response to treatment for gastrointestinal stromal tumors

In fighting cancer, the sooner doctors can determine how a patient will respond to a particular therapy, the more effective overall treatment will be. Researchers have now shown that 18F-FDG PET scans are better than CT scans at predicting response to imatinib mesylate, a drug that has recently been found effective in treating gastrointestinal stromal tumors (GISTs).

The result is significant, as the PET scan allows doctors to determine if the therapy regimen is working very early in the treatment process, providing information that will allow physicians and patients to decide as soon as possible whether to continue treatment with imatinib mesylate or try a different therapy.

The study, which was conducted by researchers at the University of Texas M.D. Anderson Cancer Center in Houston, Texas, was published in the January 2004 edition of The Journal of Nuclear Medicine. They conducted the retrospective analysis by examining the sensitivity and predictive values of PET and CT scans taken prior to therapy and then again two months after imatinib mesylate treatment had begun. While there was no significant statistical difference between the pretreatment accuracy of the two different types of scans, PET was more effective in early assessment of the patients' responses to the drug.

"In our judgment," the researchers stated, "18F-FDG PET is an excellent prognostic tool for early assessment of response to imatinib mesylate therapy." The researchers further concluded that there is not significant value in the use of CT to monitor early response to this treatment.


'"/>

Contact: Kimberly A. Bennett
kbennett@kamber.com
202-955-1253
Society of Nuclear Medicine
12-Jan-2004


Page: 1

Related medicine news :

1. Combining PET and CT scans leads to more accurate radiation therapy for lung cancer patients
2. Stanford study questions accuracy of ads for body scans
3. New technique scans electrical brainscape
4. Pet scans detect brain differences in people at risk for Alzheimers
5. 3D neutron-based medical imaging, 4D lung scans, and hitting a moving tumor
6. MRI scans could be acceptable alternative to x-rays
7. Chemical brain scans may help reassure brain tumor patients
8. Lung tumor therapies improved by combining CT and PET scans
9. New study supports use of PET scans in early diagnosis of Alzheimers disease
10. Brain scans show how placebo eases pain
11. CT scans find tiny bladder, kidney & urinary cancers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/20/2017)... ... June 20, 2017 , ... Caduceus ... is pleased to announce a new online course entitled Personal & Community ... insights and evidence-based strategies for achieving optimal well-being and teaches students how to ...
(Date:6/20/2017)... ... 20, 2017 , ... Fresenius Vascular Care, a national network of outpatient vascular ... manage a wide range of vascular conditions, has today announced its new name, Azura ... represented by more than 40 local brands, a phased rollout of the new brand ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... report contending that the introduction of school choice can promote economic development in ... charter school that has, according to the report, contributed to the economic development ...
(Date:6/20/2017)... ... June 20, 2017 , ... AMC Health , ... and success in the clinical trials market. Similar to its approach in demonstrating positive ... the clinical trials marketplace by proving the value of eVisits to support virtual studies. ...
(Date:6/20/2017)... ... June 20, 2017 , ... Leading dental clinicians, Drs. Ashlyn ... with the VATECH PaX-i and Anatomage systems. With advanced digital images and modeling capabilities, ... place dental implants precisely and restore oral health for those who are missing ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... Inc., (Nasdaq: NVAX ) today announced that data ... RSV F protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) ... the journal Vaccine (the data contained ... The Company previously announced top line results from ... F Vaccine with the goal of protecting infants from RSV ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
(Date:5/30/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will present ... Conference on Tuesday, June 13, 2017, in Rancho ... president and chief executive officer, is scheduled to present at ... can be accessed at http://ir.hill-rom.com/events.cfm . A recorded replay ... event through September 13, 2017. ...
Breaking Medicine Technology:
Cached News: